More information: Edgardo Santiago‐Rivera et al, Spider Eye Development Editing and Silk Fiber Engineering Using CRISPR‐Cas, Angewandte Chemie International Edition (2025). DOI: 10.1002/anie.

CRISPR-Cas systems are prokaryotic immune systems that confer resistance to foreign genetic elements such as plasmids and phages. CRISPR-Cas systems have been exploited for targeted genome editing.

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

A few years ago, a British company called Genus set out to design pigs immune to this germ using CRISPR gene editing. Not only did they succeed, but its pigs are now poised to enter the food chain ...

Cell and gene therapy start-up NKure Therapeutics and international gene-editing company CRISPR Therapeutics have entered into a partnership to co-develop and co-commercialise CTX112 — a next ...

CRISPR Therapeutics recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and diluted loss ...

Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs.The gene-editing innovator is at ...

Now, a first-in-human clinical trial is testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal cancers. The results show encouraging signs of safety ...

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share.

acceptphoto via Shutterstock Who’s up for some CRISPR-y bacon? This week, the Food and Drug Administration approved gene-edited pigs developed by PIC, a biotechnology company specializing in ...